Djagarian, Artur

Djagarian, Artur was paid $171K by Medicaid between Jan 2018 and Jun 2020, across 10 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 46% of everything it billed.

33Billing provider infoDJAGARIAN, ARTUR
NORMAL, IL 61761

33aNPI1598971137assigned 05/14/2007

33bProvider typeFamily Medicine Physician

28Total paid$171K

24GClaims4,399

24DCodes billed10

24AFirst – last monthJan 2018 – Jun 2020

Compared with peers

Next to other Family Medicine Physician providers in Illinois

Rank by total paid#657 of 2,947

Median peer was paid$43K

This provider vs. median4.0×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	1,228	$40K
2019	2,350	$94K
2020	821	$37K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	46%	1,382	1,207	$78K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	33%	1,397	1,112	$56K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	15%	391	341	$26K
80305		5.5%	1,101	848	$9K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	27	22	$1K
80053	Comprehensive metabolic panel	<1%	24	24	$255.40
80061	Lipid panel	<1%	12	12	$75.88
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	12	12	$70.04
36415	Collection of venous blood by venipuncture	<1%	13	13	$8.20
80348		0%	40	32	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.